Actuate Therapeutics Inc. Common stock (ACTU)

FairStock Score: 42/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I start with the business, not the ticker. Actuate Therapeutics is a clinical-stage biopharmaceutical company with no revenue in any filed period I can see. In fiscal 2025, the year ended 2025-12-31, it lost $22.2M, or $1.06 per diluted share. That was an improvement from a $27.3M loss, or $3.26 per share, in fiscal 2024, and a $24.7M loss, or $17.24 per share, in fiscal 2023, but it is still consuming capital, not producing it. For fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $4.9M and diluted EPS was -$0.20; the prior quarter, ended 2026-03-31, lost $5.6M, or -$0.24 per share. Trailing free cash flow was -$19.8M, according to FairStock, which against an $11.2M market cap at the 2026-10-13 close gives an FCF yield of -177.3%. That tells me the company burns more than its entire market value in a year. The return and health metrics are ugly: FairStock's P/E is -0.54, P/B 11.65, ROE -553.75%, ROCE -213.40%, Piotroski 0/9, and Altman Z-score -42.64. There is no moat here in the Graham sense—no product, no pricing power, no recurring revenue. The only asset that matters is elraglusib, a GSK-3 inhibitor in Phase 2 for metastatic pancreatic ductal adenocarcinoma and Phase 1/2 for refractory pediatric malignancies. If those trials work, the optionality is enormous; if they fail or require heavy dilution, equity can be worth little. At $0.47, the market is not paying for earnings because there are none; it is paying for a clinical outcome. I prefer to watch from afar until the numbers show revenue or a funded path.

In plain English: Actuate Therapeutics is a small drug development company with 12 employees. It is testing an experimental cancer medicine called elraglusib, mainly for pancreatic cancer and some childhood cancers, but it has no product sales and loses money every year. The $0.47 share price may look low, but because there are no revenues or profits, the stock is really a bet on clinical trial results rather than a cheap, stable business.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer